FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a compound with EP4 receptor antagonist activity or its pharmaceutically acceptable salt, which is effective in treating an immune disease or allergy. This invention also refers to a compound of formula (I), (II), (III), (IV), (Va) or (Vb) or its pharmaceutically acceptable salt with EP4 receptor antagonist activity, which is effective in treating an immune disease or allergy. This invention also refers to a pharmaceutical composition for treating an immune disease or allergy, which contains a therapeutically effective amount of the compound of formula (I), (II), (III), (IV), (Va) or (Vb) or its pharmaceutically acceptable salt.
EFFECT: invention refers to a method of treating an immune disease of allergy in an animal subject, including a mammal subject, which involves administering the compound of formula (I), (II), (III), (IV), (Va) or (Vb) or its pharmaceutically acceptable salt into the animal subject.
9 cl, 3 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF EP4 RECEPTOR ANTAGONIST IN TREATMENT OF CARTILAGE DISEASE | 2014 |
|
RU2663620C2 |
| SELECTIVE ANTAGONISTS OF EP4 RECEPTOR FOR CANCER TREATMENT | 2010 |
|
RU2563817C2 |
| PRODRUG 1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | 2003 |
|
RU2357962C2 |
| NOVEL COMPOUNDS AS CATHEPSIN INHIBITORS, PHARMACEUTICAL COMPOSITION BASED ON THEREOF, THEIR USING AND METHOD FOR THEIR PREPARING | 2002 |
|
RU2316546C2 |
| 2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS LEUCINE-RICH REPEAT KINASE 2 (LRRK2) MODULATORS FOR TREATMENT OF PARKINSON'S DISEASE | 2012 |
|
RU2661197C2 |
| COMBINATIONS CONTAININS Bcr-Abl/c-Kit/PDGF-RTK INHIBITORS FOR TREATING CANCER | 2007 |
|
RU2452492C2 |
| CATHEPSIN-CYSTEINE PROTEASE INHIBITORS | 2003 |
|
RU2312861C2 |
| ANTIBACTERIAL AGENT | 2000 |
|
RU2269525C2 |
| THERAPEUTIC AGENT IN DISTURBED URINATION | 2008 |
|
RU2452479C2 |
| USING EP4 RECEPTOR LIGANDS IN TREATMENT OF IL-6-MEDIATED DISEASES | 2003 |
|
RU2285527C2 |
